21:31:35 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-02-07 Bokslutskommuniké 2023
2023-11-08 Kvartalsrapport 2023-Q3
2023-08-23 Kvartalsrapport 2023-Q2
2023-06-08 Årsstämma 2023
2023-05-31 Kvartalsrapport 2023-Q1
2023-05-10 X-dag ordinarie utdelning IDOGEN 0.00 SEK
2023-02-24 Bokslutskommuniké 2022
2022-12-13 Extra Bolagsstämma 2022
2022-11-25 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-05 X-dag ordinarie utdelning IDOGEN 0.00 SEK
2022-05-04 Kvartalsrapport 2022-Q1
2022-05-04 Årsstämma 2022
2022-01-19 Bokslutskommuniké 2021
2021-10-26 Kvartalsrapport 2021-Q3
2021-08-24 Kvartalsrapport 2021-Q2
2021-05-12 X-dag ordinarie utdelning IDOGEN 0.00 SEK
2021-05-12 Kvartalsrapport 2021-Q1
2021-05-11 Årsstämma 2021
2021-02-09 Bokslutskommuniké 2020
2020-11-04 Extra Bolagsstämma 2020
2020-10-23 Kvartalsrapport 2020-Q3
2020-08-25 Kvartalsrapport 2020-Q2
2020-05-27 Split IDOGEN 10:1
2020-05-13 X-dag ordinarie utdelning IDOGEN 0.00 SEK
2020-05-12 Kvartalsrapport 2020-Q1
2020-05-12 Årsstämma 2020
2020-01-29 Bokslutskommuniké 2019
2019-10-22 Kvartalsrapport 2019-Q3
2019-08-20 Kvartalsrapport 2019-Q2
2019-06-26 X-dag ordinarie utdelning IDOGEN 0.00 SEK
2019-06-25 Årsstämma 2019
2019-04-29 Kvartalsrapport 2019-Q1
2019-02-06 Bokslutskommuniké 2018
2018-10-23 Kvartalsrapport 2018-Q3
2018-08-21 Kvartalsrapport 2018-Q2
2018-04-25 X-dag ordinarie utdelning IDOGEN 0.00 SEK
2018-04-24 Årsstämma 2018
2018-04-24 Kvartalsrapport 2018-Q1
2018-02-06 Bokslutskommuniké 2017
2017-10-26 Kvartalsrapport 2017-Q3
2017-08-30 Kvartalsrapport 2017-Q2
2017-05-18 X-dag ordinarie utdelning IDOGEN 0.00 SEK
2017-05-17 Årsstämma 2017
2017-04-24 Kvartalsrapport 2017-Q1
2017-02-15 Bokslutskommuniké 2016
2016-11-11 Kvartalsrapport 2016-Q3
2016-08-26 Kvartalsrapport 2016-Q2
2016-04-26 Kvartalsrapport 2016-Q1
2016-04-26 Årsstämma 2016
2016-02-18 X-dag ordinarie utdelning IDOGEN 0.00 SEK
2016-02-17 Bokslutskommuniké 2015
2015-10-29 Kvartalsrapport 2015-Q3
2015-08-27 Kvartalsrapport 2015-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Idogen är verksamma inom bioteknik. Bolagets affärsinriktning är att utveckla vaccinkandidater för behandling av sjukdomar som negativt påverkar immunförsvaret. Vaccinen avses att användas i de fall där det uppkommit autoimmuna sjukdomar och efter organavstötning, särskilt vid de fall där de bildats antikroppar mot intagningen av patientens ordinarie läkemedel. Bolaget grundades under 2008 och har sitt huvudkontor i Lund.
2022-11-01 19:16:00

Idogen AB announces that Agneta Edberg has been elected as new Chairman of the Board since the current Chairman of the Board, Joakim Söderström, has requested to resign from the Board of Directors at his own request as he has accepted a new position that is incompatible with being active in the Board of Directors of a public company. In addition, Niklas Wallett, who was elected to the Board of Directors at the same time as Joakim Söderström, has also requested to resign from the Board of Directors at his own request.

In September 2022, both Joakim Söderström and Niklas Wallett were elected to the Board of Directors of Idogen. Joakim Söderström was elected to be the Chairman of the Board, replacing Agneta Edberg. Joakim Söderström has now requested to resign from the Board of Directors at his own request as he has accepted a new position that is incompatible with being active in the Board of Directors of a public company and he will resume his role as a shareholder. In addition, Niklas Wallett has also requested to resign from the Board of Directors at his own request to resume his role as a shareholder.

Due to the above changes, the Board of Directors of Idogen has elected Agneta Edberg as new Chairman of the Board, effective from today. As consequence of these changes, the Board of Directors consists of Agneta Edberg, Chairman, Sharon Longhurst and Christina Herder, meaning that the Board of Directors retains a quorum. Proposal for election of a new Board of Directors will be submitted by the Nomination Committee in connection with the announcement of the notice of the Annual General Meeting 2023, at the latest.

" My goal has been to contribute to a more focused and cost-effective company. I am very pleased to see what has been accomplished so far as I now, due to work-related reasons, have to resign from the Board of Directors. I now hand over the responsibility with full confidence to the remaining members of the Board, who possesses a broad competence within business and drug development", says Joakim Söderström, resigning Chairman of the Board.

" We thank Joakim and Niklas for their short but valuable time in Idogen's Board of Directors. We will now proceed with undiminished enthusiasm to develop our IDO 8 program, where the first patient has already been enrolled," says Agneta Edberg, acceding Chairman of the Board.

For further information, please contact:

Agneta Edberg, Chairman, Idogen AB

Tel: +46 70555 75 18

E-post: edberg.agneta@gmail.com

Christina Herder, Acting CEO, Idogen AB

Tel: +46 70374 71 56

E-mail: christina.herder@idogen.com

Certified Adviser:
Vator Securities AB.

This information is such information as Idogen AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 19:16 CET on November 1, 2022.

Idogen (Nasdaq First North Growth Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient's immune system from attacking biological agents, transplanted organs or the body's own cells or tissue. The company's most advanced program, IDO 8 - now entering its clinical phase - is designed to restore the efficacy of hemophilia drugs in patients who have developed neutralizing antibodies. For these hemophiliac patients, there is significant medical need for restoring the clinical effects of their treatment with factor VIII. This is a unique market positioning that over the long term could replace immune tolerance induction (ITI) treatments, with significant market potential. The planned IDO 8 clinical trial will validate the company's technology platform and facilitate a range of other applications in fields such as organ transplants (IDO T)  and autoimmune diseases (IDO AID).More information about Idogen is available viahttps://www.idogen.com